InQpharm Group
🇲🇾Malaysia
- Country
- 🇲🇾Malaysia
- Ownership
- Private
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.inqpharm.com
Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol
Not Applicable
Completed
- Conditions
- Blood PressureLow Density Lipoprotein Cholesterol Level
- Interventions
- Dietary Supplement: IQP-AS-118Dietary Supplement: Placebo
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- InQpharm Group
- Target Recruit Count
- 54
- Registration Number
- NCT02871362
- Locations
- 🇩🇪
analyze & realize GmbH, Berlin, Germany
Efficacy and Safety of IQP-AK-102 in Reducing Appetite
Not Applicable
Completed
- Conditions
- Appetite SuppressionEnergy IntakeAppetite Regulation
- Interventions
- Device: IQP-AK-102
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2018-01-03
- Lead Sponsor
- InQpharm Group
- Target Recruit Count
- 36
- Registration Number
- NCT02774486
- Locations
- 🇩🇪
Barbara Grube, Berlin, Germany
Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects
Phase 3
Completed
- Conditions
- HyperglycemiaPrediabetes
- Interventions
- Device: PlaceboDevice: Dose 1 of IQP-VV-102Device: Dose 2 of IQP-VV-102
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- InQpharm Group
- Target Recruit Count
- 27
- Registration Number
- NCT02541344
- Locations
- 🇩🇪
analyze & realize GmbH, Berlin, Germany
Litramine for Weight Loss
Not Applicable
Completed
- Conditions
- Weight Loss
- Interventions
- Dietary Supplement: Litramine
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- InQpharm Group
- Target Recruit Count
- 99
- Registration Number
- NCT02488356
Safety and Efficacy of IQP-AK-102 in Reducing Appetite
Phase 3
Completed
- Conditions
- Weight LossAppetite Modulation (Focus of Study)
- Interventions
- Device: IQP-AK-102Device: Placebo
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- InQpharm Group
- Target Recruit Count
- 40
- Registration Number
- NCT02041754
- Locations
- 🇩🇪
Udo Bongartz, Berlin, Germany
Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea
Not Applicable
Completed
- Conditions
- Diarrhoea
- Interventions
- Device: IQP-MM-101
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- InQpharm Group
- Target Recruit Count
- 101
- Registration Number
- NCT01969214
- Locations
- 🇩🇪
analyze & realize GmbH, Berlin, Germany
Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections
Phase 3
Terminated
- Conditions
- Upper Respiratory Tract InfectionsCommon Cold
- Interventions
- Dietary Supplement: IQP-AS-105Dietary Supplement: Placebo
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- InQpharm Group
- Target Recruit Count
- 140
- Registration Number
- NCT01964885
- Locations
- 🇩🇪
Udo Bongartz, Berlin, Germany
Safety and Efficacy of IQP- AK-102 in Reducing Body Weight
Phase 3
Completed
- Conditions
- Weight Loss
- Interventions
- Dietary Supplement: IQP-AK-102Dietary Supplement: Placebo
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2016-03-08
- Lead Sponsor
- InQpharm Group
- Target Recruit Count
- 119
- Registration Number
- NCT01905956
- Locations
- 🇩🇪
Barbara Grube, Berlin, Germany
IQP-PO-101 for the Regulation of Bowel Movement Frequency
Phase 3
Completed
- Conditions
- ConstipationIrregular Bowel Movement Frequency
- Interventions
- Device: IQP-PO-101
- First Posted Date
- 2013-03-12
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- InQpharm Group
- Target Recruit Count
- 50
- Registration Number
- NCT01809587
- Locations
- 🇩🇪
Analyze & Realize Ag, Berlin, Germany
IQP-CL-101 in IBS Management
Phase 3
Completed
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Dietary Supplement: IQP-CL-101Other: Placebo
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- InQpharm Group
- Target Recruit Count
- 100
- Registration Number
- NCT01774825
- Locations
- 🇩🇪
Barbara Grube, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath